Advanced search
Publication Cover
Lung Cancer: Targets and Therapy Volume 14, 2023 - Issue
Submit an article Journal homepage
145
Views
1
CrossRef citations to date
0
Altmetric
CASE REPORT

Co-Occurring EGFR S645C and EGFR L858R in a Patient with Lung Adenocarcinoma Induced Primary Resistance to Osimertinib

Li Wang1 Department of Medical Oncology, Jiangsu Cancer Hospital & Jiangsu Institute of Cancer Research & The Affiliated Cancer Hospital of Nanjing Medical University, Nanjing, People’s Republic of China
,
Fei Quan2 The Medical Department, Nanjing Simcere Medical Laboratory Science Co., Ltd, Nanjing, People’s Republic of ChinaORCID Iconhttps://orcid.org/0000-0003-4356-0449
ORCID Icon,
Zhen Guo3 Radiology Department, Jiangsu Cancer Hospital & Jiangsu Institute of Cancer Research & The Affiliated Cancer Hospital of Nanjing Medical University, Nanjing, People’s Republic of China
,
Zhongyu Lu2 The Medical Department, Nanjing Simcere Medical Laboratory Science Co., Ltd, Nanjing, People’s Republic of China
,
Duoxia Yang2 The Medical Department, Nanjing Simcere Medical Laboratory Science Co., Ltd, Nanjing, People’s Republic of China
&
Meiqi Shi1 Department of Medical Oncology, Jiangsu Cancer Hospital & Jiangsu Institute of Cancer Research & The Affiliated Cancer Hospital of Nanjing Medical University, Nanjing, People’s Republic of ChinaCorrespondence[email protected]
ORCID Iconhttps://orcid.org/0000-0002-3578-4082
ORCID Icon
Pages 79-84 | Received 20 Jul 2023, Accepted 29 Sep 2023, Published online: 09 Oct 2023

References

  • Shi Y, Au JS, Thongprasert S, et al. A prospective, molecular epidemiology study of EGFR mutations in Asian patients with advanced non-small-cell lung cancer of adenocarcinoma histology (PIONEER). J Thorac Oncol. 2014;9(2):154–162. doi:10.1097/JTO.0000000000000033
  • Yavuz BR, Tsai CJ, Nussinov R, Tuncbag N. Pan-cancer clinical impact of latent drivers from double mutations. Commun Biol. 2023;6(1):202. doi:10.1038/s42003-023-04519-5
  • Li M, Zhou CZ, Yang JJ, et al. The in cis compound EGFR mutations in Chinese advanced non-small cell lung cancer patients. Cancer Biol Ther. 2019;20(8):1097–1104. doi:10.1080/15384047.2019.1595280
  • Zhuang X, Zhao C, Li J, et al. Clinical features and therapeutic options in non-small cell lung cancer patients with concomitant mutations of EGFR, ALK, ROS1, KRAS or BRAF. Cancer Med. 2019;8(6):2858–2866. doi:10.1002/cam4.2183
  • Larsen AK, Ouaret D, El OK, Petitprez A. Targeting EGFR and VEGF(R) pathway cross-talk in tumor survival and angiogenesis. Pharmacol Ther. 2011;131(1):80–90. doi:10.1016/j.pharmthera.2011.03.012
  • Socinski MA, Nishio M, Jotte RM, et al. IMpower150 final overall survival analyses for atezolizumab plus bevacizumab and chemotherapy in first-line metastatic nonsquamous NSCLC. J Thorac Oncol. 2021;16(11):1909–1924. doi:10.1016/j.jtho.2021.07.009
  • Lu S, Wu L, Jian H, et al. Sintilimab plus bevacizumab biosimilar IBI305 and chemotherapy for patients with EGFR-mutated non-squamous non-small-cell lung cancer who progressed on EGFR tyrosine-kinase inhibitor therapy (ORIENT-31): first interim results from a randomised, double-blind, multicentre, Phase 3 trial. Lancet Oncol. 2022;23(9):1167–1179. doi:10.1016/S1470-2045(22)00382-5
  • Chen Y, Yang Z, Wang Y, et al. Pembrolizumab plus chemotherapy or anlotinib vs. pembrolizumab alone in patients with previously treated EGFR-mutant NSCLC. Front Oncol. 2021;11:671228. doi:10.3389/fonc.2021.671228
  • Morikawa K, Iinuma M, Shinozaki Y, Nishine H, Inoue T, Mineshita M. A case of advanced adenocarcinoma genetically confirmed with EGFR/BRAF co-mutation in both primary and metastatic lesions. Ther Adv Med Oncol. 2021;13:17588359211053420. doi:10.1177/17588359211053420
  • Wang S, Li M, Zhang J, et al. Circulating tumor DNA integrating tissue clonality detects minimal residual disease in resectable non-small-cell lung cancer. J Hematol Oncol. 2022;15(1):137. doi:10.1186/s13045-022-01355-8
  • Guo L, Chen Z, Xu C, et al. Intratumoral heterogeneity of EGFR-activating mutations in advanced NSCLC patients at the single-cell level. BMC Cancer. 2019;19(1):369. doi:10.1186/s12885-019-5555-y
  • Wu Q, Luo W, Li W, Wang T, Huang L, Xu F. First-generation EGFR-TKI plus chemotherapy versus EGFR-TKI alone as first-line treatment in advanced NSCLC with EGFR activating mutation: a systematic review and meta-analysis of randomized controlled trials. Front Oncol. 2021;11:598265. doi:10.3389/fonc.2021.598265
  • Miyauchi E, Morita S, Nakamura A, et al. Updated analysis of NEJ009: gefitinib-alone versus gefitinib plus chemotherapy for non-small-cell lung cancer with mutated EGFR. J Clin Oncol. 2022;40(31):3587–3592. doi:10.1200/JCO.21.02911
  • André F, Arnedos M, Baras AS; AACR Project GENIE Consortium. AACR Project GENIE: powering Precision Medicine through an International Consortium. Cancer Discov. 2017;7(8):818–831. doi:10.1158/2159-8290.CD-17-0151
  • Berger AH, Brooks AN, Wu X, et al. High-throughput phenotyping of lung cancer somatic mutations. Cancer Cell. 2016;30(2):214–228. doi:10.1016/j.ccell.2016.06.022
  • Ikeuchi H, Hirose T, Ikegami M, et al. Preclinical assessment of combination therapy of EGFR tyrosine kinase inhibitors in a highly heterogeneous tumor model. Oncogene. 2022;41(17):2470–2479. doi:10.1038/s41388-022-02263-4
  • Luo J, Makhnin A, Tobi Y, et al. Erlotinib and trametinib in patients with EGFR-mutant lung adenocarcinoma and acquired resistance to a prior tyrosine kinase inhibitor. JCO Precis Oncol. 2021;5:55–64.
  • Eberlein CA, Stetson D, Markovets AA, et al. Acquired resistance to the mutant-selective EGFR inhibitor AZD9291 is associated with increased dependence on RAS signaling in preclinical models. Cancer Res. 2015;75(12):2489–2500. doi:10.1158/0008-5472.CAN-14-3167

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.